1983
DOI: 10.3109/10641968309048824
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetics of Spironolactone After a Single Dose: Evaluation of the true Canrenone Serum Concentrations During 24 Hours

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

1984
1984
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(4 citation statements)
references
References 12 publications
0
4
0
Order By: Relevance
“…In the dose range 1-10 mol/L, compatible with the concentrations reached by the drug in the serum after oral administration, [43][44][45][46] canrenone is able to inhibit cell growth and chemotaxis induced by PDGF without affecting basal cell proliferation and motility. To elucidate which step(s) of PDGF signaling are affected by canrenone, the effects of this drug on the downstream pathways induced by this growth factor were investigated.…”
Section: Discussionmentioning
confidence: 82%
“…In the dose range 1-10 mol/L, compatible with the concentrations reached by the drug in the serum after oral administration, [43][44][45][46] canrenone is able to inhibit cell growth and chemotaxis induced by PDGF without affecting basal cell proliferation and motility. To elucidate which step(s) of PDGF signaling are affected by canrenone, the effects of this drug on the downstream pathways induced by this growth factor were investigated.…”
Section: Discussionmentioning
confidence: 82%
“…This conclusion proved erroneous being based on non-specific fluorometric assay findings [12,13]. Assays of spironolactone and its metabolites by the use of high performance liquid chromatography (HPLC) have established that fluorometrically determined levels of canrenone overestimate true canrenone levels [14]. Using HPLC, the predominant metabolite, 7α-methylspironolactone (TMS) [15], was found to account for around 80% of the K + -sparing effect of spironolactone.…”
Section: Spironolactonementioning
confidence: 97%
“…Using this methodology, it was demonstrated that canrenone plasma concentrations were 5 times higher after potassium canrenoate administration than the same dose of spironolactone ( Dahlöf et al 1979 ). In contrast to the high proportion of canrenone generation after potassium canrenoate application, the canrenone proportion of the metabolites generated after spironolactone administration contributes only to about 15% after a single dose ( Merkus et al 1983 ) and about 23% after multiple doses ( Gardiner et al 1989 ). These results demonstrate that spironolactone and potassium canrenoate are very different in their metabolism, especially because a number of important sulfur-containing metabolites, i.e.…”
Section: Steroidal Mras (The First 45 Years Of Mra Randd)mentioning
confidence: 98%